Notification pursuant to Section 28a of the Danish Securities Trading Act
September 03, 2012 12:00 ET
|
Affitech A/S
Copenhagen and Oslo, 2012-09-03 18:00 CEST (GLOBE NEWSWIRE) --
Affitech has today received a major shareholder notification from Trans Nova Investments Ltd., who in accordance with Section 28a of...
Meddelelse i henhold til værdipapirhandelslovens § 28a
September 03, 2012 12:00 ET
|
Affitech A/S
København og Oslo, 2012-09-03 18:00 CEST (GLOBE NEWSWIRE) --
Affitech har d.d. modtaget storaktionærmeddelelse fra Trans Nova Investments Limited, som i henhold til værdipapirhandelslovens 28a,...
Resultat af offentligt købstilbud til alle andre aktionærer i Affitech A/S fremsat af Trans Nova Investments Limited
August 31, 2012 03:32 ET
|
Affitech A/S
København, 2012-08-31 09:32 CEST (GLOBE NEWSWIRE) --
På vegne Trans Nova Investments Limited offentligøres hermed meddelelse fra Trans Novas Investments Limiteds om resultatet af Trans Novas...
Results of public purchase offer to all other shareholders of Affitech A/S, made by Trans Nova Investments Limited
August 31, 2012 03:32 ET
|
Affitech A/S
Copenhagen, Denmark, 2012-08-31 09:32 CEST (GLOBE NEWSWIRE) --
On behalf of Trans Nova Investments Limited, we hereby release announcement received from Trans Nova Investments Limited concerning the...
Affitech A/S reports financial result for the first six months of 2012
August 30, 2012 11:41 ET
|
Affitech A/S
Copenhagen and Oslo, 30th August, 2012, 2012-08-30 17:41 CEST (GLOBE NEWSWIRE) --
Clinical trials sites initiated in Russia in late June 2012 by Affitech’s collaboration partner IBC Generium for...
Affitech A/S rapporterer regnskabsresultat for de første seks måneder af 2012
August 30, 2012 11:41 ET
|
Affitech A/S
København og Oslo, 30. august 2012, 2012-08-30 17:41 CEST (GLOBE NEWSWIRE) --
Etablering af kliniske forsøgssteder indledt i Rusland ultimo juni 2012 af Affitechs samarbejdspartner IBC Generium...
Første patient doseret med AT001/r84 i klinisk forsøg i Rusland
August 20, 2012 02:33 ET
|
Affitech A/S
København og Oslo, 20. august 2012, 2012-08-20 08:33 CEST (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), der udvikler antistoflægemidler, meddeler, at den første patient i det kliniske fase I...
First AT001/r84 dose in man in clinical trial in Russia
August 20, 2012 02:33 ET
|
Affitech A/S
Copenhagen and Oslo, 20th August, 2012, 2012-08-20 08:33 CEST (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced today that the first patient in the...
Affitech receives milestone payment from Roche re. LC06 antibody
August 09, 2012 08:28 ET
|
Affitech A/S
Copenhagen and Oslo, 9th August, 2012, 2012-08-09 14:28 CEST (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced today that Roche has reached the first...
Affitech modtager milepælsbetaling fra Roche vedrørende LC06 antistof
August 09, 2012 08:28 ET
|
Affitech A/S
København og Oslo, 9. august, 2012, 2012-08-09 14:28 CEST (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), der udvikler antistoflægemidler, meddeler at Roche har nået den første milepæl i en...